A Danish nationwide cohort study provided real world evidence that both glucagon-like peptide 1 receptor agonists (GLP1-RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT-2is) were associated with reduced rates of 3-point major adverse cardiovascular events (3P-MACE) and hospitalization for heart failure (HHF) compared to dipeptidyl peptidase 4 inhibitors (DPP-4is). Compared to GLP1-RAs, SGLT-2is were associated with reduced rates of HHF. The study included 35,679 participants aged ≥70 years who were new users (DPP-4is: 62%, GLP1-RAs: 16%, SGLT-2is: 23%) between 2012 and 2020. In the as-treated analysis, GLP1-RAs and SGLT-2is were associated with significantly reduced rates of 3P-MACE and HHF compared to DPP-4is. The overall incidence rate ratios (IRR) for 3P-MACE was 0.68 (GLP1-RAs vs. DPP4is) and 0.65 (SGLT-2is vs. DPP4is), while for HHF the IRR was 0.81 (GLP1-RAs vs. DPP4is) and 0.60 (SGLT-2is vs. DPP4is). These effects were predominantly independent of age. Compared to GLP1-RAs, SGLT-2is were associated with a significant reduction of HHF, with an overall IRR of 0.75. No significant difference was observed between SGLT-2is and GLP1-RAs on 3P-MACE. The results confirm the cardiovascular benefits of newer glucose-lowering drugs in elderly populations and support current guidelines. Source: https://www.thelancet.com/
Restricting sugar intake during the first 1,000 days from conception was associated with a lower…
Incidental coronary artery calcium (CAC) identified on routine nongated chest CT scans predicts future coronary…
The burden of modifiable cardiovascular risk factors—not just the total number of risk factors—is strongly…
Higher blood levels of the gut microbiome-derived metabolite trimethylamine N-oxide (TMAO) were independently associated with…
Moderate consumption of naturally caffeinated beverages, particularly coffee, is generally associated with a lower risk…
To reduce the risk of cognitive decline and/or dementia specifically, the WHO just released updated…
This website uses cookies.